Dowling & Yahnke’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Dowling & Yahnke’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$134K	Hold	7,523	–	–	0.01%	360
2022 Q2	$167K	Hold	7,523	–	–	0.01%	358
2022 Q1	$209K	Hold	7,523	–	–	0.01%	355
2021 Q4	$342K	Hold	7,523	–	–	0.02%	301
2021 Q3	$627K	Hold	7,523	–	–	0.03%	249
2021 Q2	$715K	Hold	7,523	–	–	0.04%	232
2021 Q1	$1.25M	Hold	7,523	–	–	0.09%	187
2020 Q4	$737K	Hold	7,523	–	–	0.05%	219
2020 Q3	$256K	Hold	7,523	–	–	0.02%	280
2020 Q2	$427K	Hold	7,523	–	–	0.04%	246
2020 Q1	$441K	Buy	7,523 +1,258	+20%	+$93.9K	0.04%	225
2019 Q4	$495K	Sell	6,265 -342	-5%	-$35.4K	0.04%	237
2019 Q3	$661K	Buy	+6,607	New	+$676K	0.05%	215

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Dowling & Yahnke's ONCT Position: Q3 2022 in Review

Dowling & Yahnke held its Oncternal Therapeutics, Inc. Common Stock (ONCT) position steady in Q3 2022 at 7,523 shares worth $134K. The position accounts for 0.01% of the portfolio, ranked #360.

Dowling & Yahnke first reported a position in ONCT in Q3 2019 and has held it in 13 quarters since. The position peaked at $1.25M in Q1 2021. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

Dowling & Yahnke held 7,523 shares of Oncternal Therapeutics, Inc. Common Stock worth $134K as of Q3 2022.
Dowling & Yahnke left its Oncternal Therapeutics, Inc. Common Stock share count unchanged in Q3 2022.
Oncternal Therapeutics, Inc. Common Stock made up 0.01% of Dowling & Yahnke's portfolio in Q3 2022, its #360 holding.
Dowling & Yahnke first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2019 and has held it in 13 quarters since.
Dowling & Yahnke's Oncternal Therapeutics, Inc. Common Stock position peaked at $1.25M in Q1 2021.
61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.